Vistagen announces positive results from exploratory phase 2a study of ph80 in women diagnosed with menopausal hot flashes

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that ph80, one of the company's five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory phase 2a study for the acute treatment of hot flashes (vasomo.
VTGN Ratings Summary
VTGN Quant Ranking